GeneDx Holdings Corp.
WGS
$85.74
-$5.87-6.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.35% | 70.60% | 49.01% | 48.90% | 46.01% |
| Total Other Revenue | 2.88% | -34.48% | -140.36% | -48.09% | 2.25% |
| Total Revenue | 39.56% | 66.57% | 44.22% | 44.77% | 44.70% |
| Cost of Revenue | 14.73% | 10.39% | 0.11% | -7.93% | -10.30% |
| Gross Profit | 56.11% | 115.27% | 96.88% | 128.83% | 144.67% |
| SG&A Expenses | 27.71% | 11.58% | 0.72% | -20.50% | -30.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 14.26% | -56.52% | 21.73% | -- |
| Total Operating Expenses | 20.56% | 12.93% | -3.74% | -19.16% | -24.95% |
| Operating Income | 66.57% | 158.44% | 77.55% | 79.50% | 76.60% |
| Income Before Tax | 70.07% | 120.68% | 80.31% | 37.41% | 66.76% |
| Income Tax Expenses | 645.12% | 94.16% | 72.67% | 3.06% | 44.22% |
| Earnings from Continuing Operations | 67.74% | 121.10% | 80.34% | 37.56% | 66.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.74% | 121.10% | 80.34% | 37.56% | 66.82% |
| EBIT | 66.57% | 158.44% | 77.55% | 79.50% | 76.60% |
| EBITDA | 113.47% | 287.67% | 92.89% | 87.01% | 83.11% |
| EPS Basic | 70.13% | 119.68% | 81.29% | 40.37% | 74.45% |
| Normalized Basic EPS | 72.23% | 206.80% | 76.00% | 44.24% | 74.97% |
| EPS Diluted | 70.13% | 119.68% | 81.29% | 40.37% | 74.45% |
| Normalized Diluted EPS | 72.23% | 206.80% | 76.00% | 44.24% | 74.97% |
| Average Basic Shares Outstanding | 8.00% | 7.20% | 5.07% | 4.72% | 29.91% |
| Average Diluted Shares Outstanding | 8.00% | 7.20% | 5.07% | 4.72% | 29.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |